These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 38294337)

  • 1. Real-world evidence on the effectiveness and safety of gliclazide MR 60 mg in Bangladeshi patients with Type II diabetes during fasting: a sub-analysis from the global DIA-RAMADAN study.
    Uddin MF; Khan MA; Selim S; Sultana N; Sayem MA; Iftekhar MM; Habib MB; Akter N; Khan S
    J Comp Eff Res; 2024 Feb; 13(2):e230132. PubMed ID: 38294337
    [No Abstract]   [Full Text] [Related]  

  • 2. Indonesia DIA-RAMADAN Study: A Real-life, Prospective and Observational of Gliclazide MR in Type-2 Diabetes Patients During Ramadan Fasting.
    Soelistijo SA; Aman AM; Zufry H; Pranoto A; Rudijanto A; Hassanien M
    Acta Med Indones; 2022 Jan; 54(1):3-9. PubMed ID: 35398820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A real-world study in patients with type 2 diabetes mellitus treated with gliclazide modified-release during fasting: DIA-RAMADAN.
    Hassanein M; Al Sifri S; Shaikh S; Abbas Raza S; Akram J; Pranoto A; Rudijanto A; Shaltout I; Fariduddin M; Mohd Izani Wan Mohamed W; Al Awadi F; Alessa T;
    Diabetes Res Clin Pract; 2020 May; 163():108154. PubMed ID: 32330510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the effectiveness and tolerability of gliclazide modified release 60 mg in patients with type 2 diabetes observing fasting during Ramadan in Pakistan: An analysis from the global DIA-RAMADAN study.
    Raza SA; Akram J; Aamir AH; Ahmedani Y; Hassan MI
    Diabetes Res Clin Pract; 2021 Nov; 181():109086. PubMed ID: 34634390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind, randomized trial, including frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study.
    Hassanein M; Abdallah K; Schweizer A
    Vasc Health Risk Manag; 2014; 10():319-26. PubMed ID: 24920915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of hypoglycemia in patients with type 2 diabetes treated with gliclazide versus DPP-4 inhibitors during Ramadan: A meta-analytical approach.
    Mbanya JC; Al-Sifri S; Abdel-Rahim A; Satman I
    Diabetes Res Clin Pract; 2015 Aug; 109(2):226-32. PubMed ID: 26003888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world Safety and Effectiveness of Insulin Glargine 300 U/mL in Participants with Type 2 Diabetes Mellitus During the Period of Ramadan in Four Countries (Egypt, Jordan, Lebanon, and Turkey): A Prospective Observational Study.
    Hassanein M; Shaltout I; Malek R; Assaad Khalil S; Ballout H; Annabi F; Shereen M
    Curr Diabetes Rev; 2024; 20(5):e110823219694. PubMed ID: 37581325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Descriptive Regional Subanalysis of a Real-World Study in Patients with Type 2 Diabetes Treated with Gliclazide MR During Fasting: DIA-RAMADAN.
    Hassanein M; Al Sifri S; Shaikh S; Raza SA; Akram J; Rudijanto A; Shaltout I; Fariduddin M; Mohamed WMIBW; Al Awadi F; Durocher A; Cortese V; Alessa T
    Diabetes Ther; 2021 Jun; 12(6):1703-1719. PubMed ID: 33974216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during Ramadan.
    Devendra D; Gohel B; Bravis V; Hui E; Salih S; Mehar S; Hassanein M
    Int J Clin Pract; 2009 Oct; 63(10):1446-50. PubMed ID: 19678856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world safety and effectiveness of insulin glargine 300 U/mL in participants with type 2 diabetes who fast during Ramadan: The observational ORION study.
    Hassanein M; Buyukbese MA; Malek R; Pilorget V; Naqvi M; Berthou B; Shaltout I; Kumar Sahay R
    Diabetes Res Clin Pract; 2020 Aug; 166():108189. PubMed ID: 32360709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maintenance of glycaemic control with the evening administration of a long acting sulphonylurea in male type 2 diabetic patients undertaking the Ramadan fast.
    Zargar AH; Siraj M; Jawa AA; Hasan M; Mahtab H
    Int J Clin Pract; 2010 Jul; 64(8):1090-4. PubMed ID: 20455956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and effectiveness of iGlarLixi in adults with type 2 diabetes mellitus from Gulf countries during Ramadan holy month: A subgroup analysis of the SoliRam observational study.
    Hassanein M; El Naggar A; Al Sheikh A; Djaballah K; Saeed M; Melas-Melt L; AlSifri S
    Diabetes Res Clin Pract; 2024 Mar; 209():111567. PubMed ID: 38341039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study.
    Hassanein M; Hanif W; Malik W; Kamal A; Geransar P; Lister N; Andrews C; Barnett A
    Curr Med Res Opin; 2011 Jul; 27(7):1367-74. PubMed ID: 21568833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of efficacy and tolerability of gliclazide and metformin combination: a multicentric study in patients with type 2 diabetes mellitus uncontrolled on monotherapy with sulfonylurea or metformin.
    Pareek A; Chandurkar N; Zawar S; Agrawal N
    Am J Ther; 2010; 17(6):559-65. PubMed ID: 20093927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Double-blind, randomized, multicentre study of the efficacy and safety of gliclazide-modified release in the treatment of Chinese type 2 diabetic patients.
    Lu CH; Chang CC; Chuang LM; Wang CY; Jiang YD; Wu HP
    Diabetes Obes Metab; 2006 Mar; 8(2):184-91. PubMed ID: 16448522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is Ramadan fasting safe in type 2 diabetic patients in view of the lack of significant effect of fasting on clinical and biochemical parameters, blood pressure, and glycemic control?
    M'guil M; Ragala MA; El Guessabi L; Fellat S; Chraibi A; Chabraoui L; Israili ZH; Lyoussi B
    Clin Exp Hypertens; 2008 Jul; 30(5):339-57. PubMed ID: 18633757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NIDDM: new once-daily intervention for type 2 diabetes mellitus: Diaprel MR.
    Ionescu-Tîrgovişte C; Gavrilă L; Brădescu OM; Guja C
    Rom J Intern Med; 2004; 42(2):431-40. PubMed ID: 15529633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world safety and effectiveness of iGlarLixi in people with type 2 diabetes who fast during Ramadan: The SoliRam observational study.
    Hassanein M; Malek R; Shaltout I; Sahay RK; Buyukbese MA; Djaballah K; Pilorget V; Coudert M; Al Sifri S;
    Diabetes Metab Syndr; 2023 Feb; 17(2):102707. PubMed ID: 36680967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Attitude and safety of patients with diabetes observing the Ramadan fast.
    Ba-Essa EM; Hassanein M; Abdulrhman S; Alkhalifa M; Alsafar Z
    Diabetes Res Clin Pract; 2019 Jun; 152():177-182. PubMed ID: 30946851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of Ramadan fasting on metabolic profile among type 2 diabetes mellitus patients: A meta-analysis.
    Tahapary DL; Astrella C; Kristanti M; Harbuwono DS; Soewondo P
    Diabetes Metab Syndr; 2020; 14(5):1559-1570. PubMed ID: 32947756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.